Want to see FR:ALMKT full AI Analyst Report?

MAUNA KEA TECHNOLOGIES (ALMKT) Price & Analysis

1 Followers

ALMKT Stock Chart & Stats

€0.08

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.08

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.07 - €0.23

Previous CloseN/A

Volume123.00K

Average Volume (3M)830.17K

Market Cap

€32.04M

Enterprise Value€20.71M

Total Cash (Recent Filing)€4.97M

Total Debt (Recent Filing)€12.08M

Price to Earnings (P/E)8.2

Beta0.85

Next Earnings

Oct 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding192,097,270

10 Day Avg. Volume1,028,958

30 Day Avg. Volume830,169

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-2.65

Price to Sales (P/S)1.55

P/FCF Ratio-3.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€7.75M

Bulls Say, Bears Say

Bulls Say

High Gross Margins And Revenue ReboundSustained ~75% gross margins indicate durable product-level economics tied to specialized imaging probes and systems. Combined with a 2025 revenue rebound, this suggests the company can scale revenue with attractive unit margins, supporting long-term profitability if operating costs are controlled and installed base grows.

Consumable-driven Recurring Revenue ModelA business model where system placements create an installed base and recurring probe sales provides structural, annuity-like revenue. This supports predictable consumable demand per procedure, incentivizes customer lock-in via compatibility, and underpins long-term revenue visibility as clinical adoption widens.

Material Debt Reduction In 2025Substantially lower debt reduces interest and refinancing pressure and extends financial runway, improving solvency metrics. This deleveraging materially lowers short-term default risk and gives management more flexibility to prioritize operational rebuilding and commercial investments over urgent liability management.

Bears Say

Persistent Cash Burn And Negative EquityOngoing negative operating cash flows and accumulated deficits force reliance on external funding or balance-sheet maneuvers, raising dilution and refinancing risk. Negative equity constrains strategic options, limits ability to raise unsecured capital, and amplifies vulnerability to adverse market or reimbursement shifts.

Operating Losses Despite Strong Gross MarginsSevere operating losses imply high fixed or SG&A costs relative to current revenue scale; accounting net profit in 2025 is not supported by operations. Persisting operating deficits mean scale is insufficient to absorb overheads, making durable profitability dependent on sustained revenue expansion or structural cost cuts.

Small, Volatile Revenue BaseSharp year-to-year swings on a sub-€10M revenue base indicate demand volatility and limited scale. This reduces revenue predictability, hinders operating leverage, and increases sensitivity to single-customer, reimbursement, or adoption shifts, challenging consistent margin expansion and investment planning.

ALMKT FAQ

What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?

MAUNA KEA TECHNOLOGIES lowest stock price was €0.07 and its highest was €0.23 in the past 12 months.

What is MAUNA KEA TECHNOLOGIES’s market cap?

MAUNA KEA TECHNOLOGIES’s market cap is €32.04M.

When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?

MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Oct 08, 2026 which is in 97 days.

How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?

MAUNA KEA TECHNOLOGIES released its earnings results on Apr 22, 2026. The company reported €0.19 earnings per share for the quarter, beating the consensus estimate of N/A by €0.19.

Is MAUNA KEA TECHNOLOGIES overvalued?

According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MAUNA KEA TECHNOLOGIES pay dividends?

MAUNA KEA TECHNOLOGIES does not currently pay dividends.

What is MAUNA KEA TECHNOLOGIES’s EPS estimate?

MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MAUNA KEA TECHNOLOGIES have?

MAUNA KEA TECHNOLOGIES has 192,097,270 shares outstanding.

What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?

MAUNA KEA TECHNOLOGIES reported an EPS of €0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.622%.

Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?

Currently, no hedge funds are holding shares in FR:ALMKT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

MAUNA KEA TECHNOLOGIES

Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.